Monograph

J05AF05 - Lamivudine

Propably not porphyrinogenic

Side effects

Common adverse reactions of lamivudine that can be confused with an acute porphyric attack are nausea, vomiting, abdominal pain and diarrhoea. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.

Rationale

Lamivudine is not metabolized by CYP450 enzymes, and is not an inducer or a mechanism-based inhibitor of CYP450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.

Chemical description

Nucleoside analogue

Therapeutic characteristics

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV-1 and hepatitis B. It is administered orally.

Metabolism and pharmacokinetics

Lamivudine is not a substrate, inhibitor or inducer of CYP450 enzymes (Johnson 1999, SPC). The majority of lamivudine is eliminated unchanged through the kidney, and only 5 % is metabolized to trans-sulfoxide (Kumar 2010).

Similar drugs

Explore alternative drugs in similar therapeutic classes J05A / J05AF or go back.

References

#	Citation details	PMID
*	Scientific articles
1.	Clinical pharmacokinetics of lamivudine. Johnson MA, Moore KH, et al. Clin Pharmacokinet. 1999 Jan;36(1):41-66.
2.	Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):105-14.	20001611
*	Summary of Product Characteristics
3.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Epivir).

Citation details

PMID

Scientific articles

Clinical pharmacokinetics of lamivudine.

Johnson MA, Moore KH, et al. Clin Pharmacokinet. 1999 Jan;36(1):41-66.

Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):105-14.

20001611

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Epivir).

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames

Epivir 10 mg/ml, drank · Epivir 150 mg, tabletten · Epivir 300 mg, omhulde tabletten · Lamivudine Accord 100 mg, filmomhulde tabletten · Lamivudine Accord 150 mg, filmomhulde tabletten · Lamivudine Accord 300 mg, filmomhulde tabletten · Lamivudine Aurobindo 150 mg, filmomhulde tabletten · Lamivudine Aurobindo 300 mg, filmomhulde tabletten · Lamivudine Sandoz 100 mg, filmomhulde tabletten · Lamivudine Sandoz 150 mg, filmomhulde tabletten · Lamivudine Sandoz 300 mg, filmomhulde tabletten · Lamivudine Teva 100 mg, filmomhulde tabletten · Lamivudine Teva Pharma BV, 150 mg filmomhulde tabletten · Lamivudine Teva Pharma BV, 300 mg filmomhulde tabletten · Zeffix 100 mg tabletten · Zeffix 5 mg/ml oplossing

Epivir 10 mg/ml sol. buv. · Epivir 150 mg compr. pellic. · Epivir 300 mg compr. pellic. · Lamivudine Teva 100 mg compr. pellic. · Lamivudine Teva Pharma B.V. 150 mg compr. pellic. · Lamivudine Teva Pharma B.V. 300 mg compr. pellic. · Zeffix 100 mg compr. pellic. · Zeffix 5 mg/ml sol. buv.

Epivir · Epivir 10 mg/ml Solucion Oral · Epivir 150 mg Comprimidos Recubiertos con Pelicula · Lamivudina · Lamivudina Accord 100 mg Comprimidos Recubiertos con Pelicula efg · Lamivudina Accord 300 mg Comprimidos Recubiertos con Pelicula efg · Lamivudina Aurovitas 300 mg Comprimidos Recubiertos con Pelicula efg · LAMIVUDINA NORMON 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG · LAMIVUDINA NORMON 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG · LAMIVUDINA TEVA 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG · Lamivudina Teva Pharma b.v. Comprimidos Recubiertos efg · ZEFFIX 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA · ZEFFIX 5 mg/ml SOLUCION ORAL